CD274 and neoplasm: Nivolumab binds programmed death-1 (PD-1) with high affinity, blocks its interactions with programmed cell death-ligand 1 (PD-L1) and programmed cell death-ligand 2 (PD-L2), and stimulates memory response to tumor antigen-specific T-cell proliferation [1].